← Human Trials & Peer-Reviewed Studies
Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes
Plain-language guide to PMID 10332685 (1999): double-blind randomized controlled trial study of Insulin Aspart in 22 subjects.
Key Facts
- PMID
- 10332685
- Journal
- Diabetes care
- Year
- 1999
- Study type
- Randomized Controlled Trial
- Authors
- Lindholm A et al. (3 authors)
- DOI
- 10.2337/diacare.22.5.801
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin Aspart, published as a randomized controlled trial.
Insulin aspart is a novel rapid-acting insulin analog.
This study was performed to compare the postprandial serum glucose control after administration of insulin aspart with that of unmodified human insulin.
Who Took Part
The study group was 22 subjects.
By PubMed's age tags, the people studied were adults, men only.
The trial was a double-blind double-dummy injection three-way cross-over study in 22 subjects with type 1 diabetes.
How the Study Was Run
The design is described as randomized, double-blind and crossover.
Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.
Neither the subjects nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.
In the crossover set-up each of the subjects took both Insulin Aspart and the comparison in turn, acting as their own control.
Insulin aspart was injected subcutaneously immediately before the meal, and human insulin was injected subcutaneously 30 min before the meal or immediately before the meal.
What Was Measured
The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin, Insulin Aspart, Metabolic Clearance Rate and Postprandial Period.
What This Means in Plain Language
The paper is a randomized, double-blind and crossover study of Insulin Aspart in 22 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 1999 (Diabetes care), a journal based in United States.
More context: the Insulin Aspart compound page, all human trials.
Our Notes on the Compound
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.